Astellas fleshes out more PhIII data for Claudin 18.2 drug
Just weeks after unveiling the first detailed late-stage data on its CLDN18.2 drug, Astellas is beefing up the data package with results from a second …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.